Radiochimioterapia (RCT) neoajuvantã reprezintã o modalitate de management acceptatã de multe centre în abordarea adenocarcinomului de joncåiune esogastricã (JEG) avansat local Scopul: Influenţa RCT neoadjuvante asupra rezultatelor postoperatorii imediate şi la distanţă la pacienţii cu adenocarcinoame de JEG avansate local. Metoda: În Centrul de Excelenţă în Chirurgia Esofagiană de la Spitalul Sfânta Maria între 2010-2017 au fost trataţi 62 pacienţi cu adenocarcinoame de JEG avansate local. Conform clasificării Siewert şi Stein lotul a cuprins tipul I -11 pacienţi, tipul II -18 pacienţi şi tipul III -33 pacienţi. Radichimioterapie neoadjuvantă au efectuat 17 pacienţi. Tratamentul chirurgical la cei 62 de pacienţi rezecaţi a fost: esogastrectomie totală pe cale abdominală -40 pacienţi, esofagectomie subtotală cu rezecţia micii curburi gastrice -13 pacienţi, esofagectomie subtotală prin triplu abord McKeown -5 pacienţi şi esofagectomie abdomino-cervicală Orringer -4 pacienţi. Rezultate: Morbiditatea postoperatorie a fost de 46,77% şi a fost reprezentată în principal de fistule la 17 pacienţi şi complicaţii pulmonare de tipul pleureziilor, pneumoniilor si sindromului de detresă respiratorie la 12 pacienţi. S-au constatat fistule la 15 pacienţi: gradul 1 -2 pacienţi, gradul 2 -10 pacienţi, gradul 3-5 pacienţi. Mortalitatea postoperatorie a fost de 4.8%. (p_value = 0.017980 Fisher's Exact Test). Regresia stadiului iniţial s-a intâlnit
Introduction
Adenocarcinomas of esophageal junction have an increasing incidence lately, especially in western countries and unlike Asia, in these countries the presentation is delayed and usually it's in an advanced stage. Currently, there is no consensus regarding the management of patients with advanced local esophagogastric junction adenocarcinomas. If there is unanimity for Siewert I tumors regarding surgical technique, for Siewert II and III tumors there is still a matter of debate regarding surgical approach, operative risks that may occur and the postoperative complications (1) .
An important factor to be taken into account after junction adenocarcinomas surgery is the risk of fistula (somewhere between 10-15%) and the complications that may occur with it (2,3).
Between 1996 and 2013, there have been numerous studies of chemotherapy or chemotherapy associated with preoperative radiotherapy, which concluded that neoadjuvant radiochemotherapy (and even chemotherapy alone) leads to a better postoperative outcome and longer survival for patients with advanced tumor stage comparative with surgical treatment only. According to several studies, neoadjuvant RCT can act on both microadenopathies and primary tumors, increasing the chance of complete resection and, in some cases, achieving a complete pathological response (4, 5) .
Materials and Method
A retrospective study was conducted on a group of 62 patients with locally advanced la 7 pacienţi. Nu am întâlnit diferenţe semnificativ statistice în ceea ce priveşte supravieţuirea la distanţă. The group consisted of 45 men and 17 women with average age of 64. These were assessed using common investigation methods such as oespphagogastroduodenoscopy (OGD) with biopsy, barium meal, ultrasound and computerized tomography, but endoscopic ultrasound (EUS) and PET-CT were also used for a limited number of patients. The preoperative allocation into Siewert classification was based mainly on the correlation of the endoscopic location of tumor with the radiological aspect (Fig.1) .
According to the Siewert classification, the group comprised of type I -11 patients, type II -18 patients and type III -33 patients. Neoadjuvant RCT was indicated for 17 patients.
The proposed preoperative treatment was radiotherapy 41.4-50.4 Gy (1.8-2.0Gy/d) with concurrent chemotherapy (fluoropyrimidines and oxaliplatin usual regimen, modified or adjusted in case of toxicity). The gross target volume included the regional lymph nodes identified at CT togheter with the clinical target volume (CTV) which is the primary tumor plus 3-4 cm superior and inferior and 1 cm lateral.
After preoperative treatment, the patients were endoscopically, tomographically and radiologically assessed regarding response to treatment (Fig. 2) . The surgical treatment of these patients was, depending on the location of the tumor, according to the Siewert classification, by subtotal esophagectomy with lymphadenectomy on 1,2 or 3 fields. The technique applied to the 62 patients was: abdominal extended gastrectomy in 40 patients, subtotal esophagectomy with resection of lesser curvature -Ivor Lewis procedure in 13 patients, esophagectomyMcKeown approach (3 incisions) in 5 patients and transhiatal esophagectomy (Orringer procedure) in 4 patients.
The abdominal approach of Siewert type III tumors was performed by abdominal medial incision and a dissection of the lower thoracic esophagus transhiatally (Hill technique) (Fig. 3) .
The Ivor-Lewis esophagectomy is combining the abdominal approach with the right thoracotomy and offers the possibility of a better dissection of the mediastinal lymph nodes, but at the same time it is a technique in which the anastomosis of the esophagus is placed in the thorax (Fig. 4) .
Another technique used was abdominal, thoracic and cervical esophagectomy, the McKeown technique (3 incisions). This adds a left cervical incision for anastomosis, placing it at the cervical level, thus avoiding major complications and providing the possibility of easier treatment of the fistula.
The transhiatal approach (Orringer), which involves a medial abdominal incision and a cervical incision, has a cervical anastomosis between remaining esophagus and tubulized stomach (Fig. 7) , this technique having the advantages of lower postoperative thoracic complications than the transthoracic approach, but cervical anastomosis presents a higher risk of fistula according to numerous studies.
Anastomoses were hand sewed in 23 patients, mainly interrupted absorbable sutures of Maxon 3-0, circular mechanical anastomoses were also performed in 39 patients, especially in the case of abdominal Hill approach, where manual anastomosis is performed with high difficulty or transthoracic approach due to the vital risk of anastomotic fistula with this localization. Anastomotic (Fig. 9 ). The anastomotic partner of the esophagus was the stomach in 21 patients and the jejunum in 41 patients.
Results
It was analyzed the influence of neoadjuvant RCT on postoperative morbidity generated by anastomotic fistula and pulmonary complications, immediate or distant mortality and postoperative histopathological criteria: pT or ypT, pN or ypN, or pTNM or ypTNM (Table 1) . Postoperative morbidity was 46.77% and was mainly represented by fistulas in 17 patients and pulmonary complications such as pleurisy, pneumonia or ARDS in 12 patients. Fistula was found in 15 patients: grade 1 -2 patients, grade 2 -10 patients, grade 3 -5 patients.
There were no statistically significant differences between patients that received and those who did not received neoadjuvant radiotherapy in the incidence of anastomotic fistula or pulmonary complications. Also no statistically significant differences between the two groups of patients were observed in fistula incidence by reference to the 2015 Esofagectomy Complications Consensus Group (ECCG).
Postoperative mortality was 4.8% -3 patients died in the neoadjuvant RCT group one due to lung complications, one of sepsis following a grade 3 fistula and one by decompensated hepatic cirrhosis in postoperative day 3.
Data processing revealed a statistically significant difference in postoperative mortality in the two groups of patients. Neoadjuvant RCT significantly influenced postoperative mortality.
All patients in the batch were operated and We have noticed a significant difference in ratio between pT and ypT category (p_value = 0.015274, Likelihood Ratio) of the ones that received preoperative RCT and the other group who did not, as follows: for T0 category (pTNM), between those with preoperative treatment (11.8%) and those without (0.0%) -2 patients with neoadjuvant RCT had no residual tumor; and for T2 category (pTNM) between those with preoperative treatment (35.3%) and those without (8.9%) -patients that did not received preoperative RCT had a deeper parietal tumor invasion compared with the ones that received chemoradiation. In the neoadjuvant RCT group no T4 category tumors were reported.
We found a significant difference between ypTNM stage for patients with neoadjuvant RCT and pTNM stage for patients that undergo surgery first (p_value = 0.000117, Likelihood Ratio), as follow: stage II pTNM between preoperative RCT (40.0%) and no preoperative RCT (0.0%) -postoperative stage ypTNM showed that 7 patients with neoadjuvant RCT were found in stage I (1 patient) and II (6 patients), even though these patients had locally advanced tumors at baseline.
A statistically significant difference was also observed by comparing the number of metastatic lymph nodes between the two groups of patients (p_value = 0.004461 MannWhitney Test). Invaded lymph nodes found were significantly less in number following neoadjuvant RCT.
Median follow up for patients was 35,5 months. On January 1, 2018, 9 patients out of 17 patients with preoperative chemoradiation and 24 out of 45 patients without RCT, were surviving.
There was no significant difference in the statistical analysis of deceased patients.
Survival Analysis -Neoadjuvant RCT Influence on overall survival -Statistical Data Processing Survival analysis shows similar survival curves. However, 5 years survival in patients with neoadjuvant RCT was 0% while for patients without neoadjuvant RCT 5 years survival rate was 50.9%.
a. Estimation is limited to the largest survival time if it is censored.
Overall survival comparison at 6, 12, 18, 24, 36, 48, 60 months between preoperative RCT group and no preoperative RCT group did not show statistically significant differences.
Discussions
Despite the increased incidence of gastroesophageal junction adenocarcinoma in western countries (6), the optimal therapeutic protocol for locally advanced disease remains controversial. There is a poor outcome with surgery as the only therapeutic way. Multimodal therapy improves survival, but there is a lack of consensus regarding clinical approach throughout the world.
Many literature data suggest that preoperative chemotherapy or chemoradiation offers better results compared to surgery alone for esophagogastric junction adenocarcinoma (7, 8) . Patients with locally advanced tumors benefit from neoadjuvant therapy compared to surgery only (9) .
Neoadjuvant chemotherapy is better tolerated than adjuvant therapy and therefore dose level established is likely to be maintained in a higher number of patients. Also, neoadjuvant treatment can induce tumor downstaging, raising the possibility of complete surgical resection. This may be particularly important in western populations because these patients often have more advanced tumors than Asian patients (10) .
Despite adequate resection, a significant number of patients with esophagogastric adenocarcinoma relapse locally (11) . Preoperative chemoradiation can reduce local recurrences and improve overall pathological response rates, a variable associated with improved survival (11) (12) (13) .
Because many patients after esophagogastrectomy fail to recover to the point of tolerability for postoperative therapy, chemoradiotherapy for esophanogastric junction tumors is rarely applied (14, 15) .
In the studied group 17 of the patients included received neoadjuvant RCT, the remaining patients had surgery first, the complementary treatment being indicated in accordance with the histopathological criteria of the resection specimen. The neoadjuvant RCT at the dose of 45-50.4 Gy in 25-28 Postoperative morbidity was 40% compared to the literature that revealed lower morbidity (around 17.9%). In the group with neoadjuvant RCT, there was no statistically significant difference in postoperative morbidity. RCT did not influenced the occurrence of anastomotic fistula or it`s severity, nor the pulmonary complications, comparable to some published studies (16) .
Tumor regression was noticed in 7 patients after initial chemoradiation and increased numbers of T1-T2 tumors in the group compared with the monotherapy group (41% vs. 0%) compared to other literature data. (17) Radiochemotherapy significantly improved complete pathological response rate (17%) compared to other studies (15.6% versus 2.0%, p = 0.03, respectively, 29% complete pathological response rate) and significantly decreased the number of metastatic lymph nodes (p = 0.004), also supported by other literature studies (17, 18) . Mortality was 4.8% similar to other literature data. All patients in the neoadjuvant RCT lot determined a statistically significant difference in postoperative mortality, unlike some literature data showing that neoadjuvant RCT did not influence postoperative mortality (16) .
There was no statistically significant difference in the long-term survival curves among the lot of patients with neoadjuvant RCT versus those who did not received RCT.
Similar data are reported by Urba et al. (19) who did not notice any survival advantage in preoperative radiochemoterapy patients, probably due to insufficient statistical power. A larger Australian Phase III study (n = 265), which included gastroesophageal junction tumors, reported a significantly better rate of R0 resection after radiochemotherapy (80% vs. 59%, p = .0002), but without improvement of overall survival or disease free survival (20) .
In contrast to our results, many literature data suggest that mean global survival was significantly higher in those with RCT and surgery than in the surgical only group (49.4 months vs. 24.0 months). The results were better for preoperative RCT and surgery for 3 year survival (47.4% vs. 2.7%) (21) .
Walsh et al. showed a net improvement in survival after multimodal therapy (global survival at 3 years of 32% vs. 6%, p = .01)
An justification for the results obtained may be the small number of patients included in the study group and the fact that patients who did not received neoadjuvant RCT followed a postoperative treatment, unlike other study groups where surgery was the only therapy.
We strongly agree with literature data that patients who underwent an esophagogastrectomy resection and have lymph node metastases on the resection specimen require some form of adjuvant treatment (22) .
There are authors who consider that patients with esophagogastric junction adenocarcinomas are more susceptible to develop distant disease and therefore a systemic approach to chemotherapy can be more beneficial than an localized only treatment strategy for these patients (23) .
Long-term follow-up of esophagogastric junction adenocarcinoma patients validate the overall survival benefits of neoadjuvant chemoradiotherapy. This improvement is clinically relevant for both squamous carcinoma and adenocarcinoma subtypes (24, 25) .
Neoadjuvant radiochemotherapy can lead to tumor regression, decreased incidence of local recurrence, and improved overall survival of patients. A therapeutic strategy that includes neoadjuvant radiochimioterapy should be implemented in clinical practice for the treatment of locally advanced esophagogastric junction adenocarcinomas (26, 27) .
Conclusions
Neoadjuvant RCT did not statistically influence postoperative morbidity as opposed to postoperative mortality.
Preoperative treatment RCT determined regression of the cT and cN criteria and the cTNM stage. Overall survival of patients with neoadjuvant RCT was similar with that of patients with surgical treatment and postoperative adjuvant chemotherapy.
